Trial Profile
Response to Carfilzomib based therapy in patients with multiple myeloma progressing on Bortezomib based therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2017
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology